Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3       On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25     Radiopharm Theranostics (ASX: RAD,OTC:RDPTF, Nasdaq: RADX, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical…